• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Carmell Corporation

    7/17/24 7:30:20 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care
    Get the next $CTCX alert in real time by email
    424B3 1 424b3_annual_mtg_vote_07.htm 424B3 424B3

     

    Filed Pursuant to Rule 424(b)(3)
    Registration No. 333-279329

    Prospectus Supplement No. 1

    (to prospectus dated June 5, 2024)

    img226570933_0.jpg 

    1,331,452 Shares of Common Stock

    This prospectus supplement amends and supplements the prospectus of Carmell Corporation (“we,” “us,” or “our”) dated June 5, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-279329). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 17, 2024 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this prospectus supplement.

    This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

    Our common stock is listed on The Nasdaq Capital Market under the symbol “CTCX.” On July 16, 2024, the last reported sale price of our common stock was $1.52 per share.

    We are a “smaller reporting company” and have elected to comply with certain reduced public company reporting requirements. In addition, we are an “emerging growth company,” as that term is defined under the federal securities laws and, as such, are subject to certain reduced public company reporting requirements.

    Investing in our securities involves a high degree of risk. Before making an investment decision, please read the information under “Risk Factors” beginning on page 7 of Prospectus and elsewhere in any supplements for a discussion of information that should be considered in connection with an investment in our securities.

    Neither the SEC or any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus. Any representation to the contrary is a criminal offense.

    The date of this prospectus supplement is July 17, 2024.

     

     


     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 12, 2024

     

     

    Carmell Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40228

    86-1645738

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2403 Sidney Street, Suite 300

     

    Pittsburgh, Pennsylvania

     

    15203

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 281 297-8276

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CTCX

     

    The Nasdaq Stock Market LLC

    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

     

    CTCXW

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    Carmell Corporation, a Delaware corporation (the “Company”), held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on July 12, 2024. As of the close of business on May 31, 2024, the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting, there were 20,567,757 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), outstanding. Holders of 11,471,693 shares of Common Stock (representing 56%% of the shares of Common Stock outstanding as of the close of business on the Record Date) were present or represented by proxy at the Annual Meeting, constituting a quorum. During the Annual Meeting, the stockholders of the Company voted on two proposals described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on June 14, 2024. The results for each matter voted on by the stockholders during the Annual Meeting were as follows:

    Proposal 1: The stockholders of the Company elected Richard Upton as a Class I director to the Company’s Board of Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 and until his successor is duly elected and qualified. The results of the stockholders’ vote with respect to the election of Mr. Upton were as follows:

    Nominee

    Term Expiring

    For

    Withhold

    Richard Upton

    2027

    9,525,320

    24,465

    Broker Non-Votes: 1,921,908

    Proposal 2: The stockholders of the Company ratified the selection of Adeptus Partners, LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:

    For

    Against

    Abstain

    11,455,591

    12,663

    3,439

    Broker Non-Votes: 0

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Carmell Corporation

     

     

     

     

    Date:

    July 17, 2024

    By:

    /s/ Rajiv Shukla

     

     

     

    Rajiv Shukla
    Chairman and Chief Executive Officer

     

     


    Get the next $CTCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CTCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bracken-Ferguson Kendra

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:13:51 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gregory Kathryn

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Cassaday Bryan J.

    4 - Carmell Corp (0001842939) (Issuer)

    11/8/24 5:00:12 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Upton Richard A bought $2,336 worth of shares (5,000 units at $0.47), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/16/24 4:30:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Frisch Scott M. bought $515 worth of shares (1,009 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:11 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Director Gregory Kathryn bought $643 worth of shares (1,260 units at $0.51) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    9/10/24 4:30:16 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Elevai Skincare Acquisition

    PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. ("Elevai"), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) ("PMGC") and Elevai, its wholly owned subsidiary (the "Acquisition"). At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 mill

    1/16/25 8:00:28 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out

    PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The Private Placement was priced at a slight premium t

    1/3/25 8:00:03 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    SEC Filings

    View All

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:01:17 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/26/25 5:00:09 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Carmell Corporation

    424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

    3/10/25 8:53:40 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Leadership Updates

    Live Leadership Updates

    View All

    CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

    Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

    3/10/25 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

    PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi

    7/29/24 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

    PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co

    3/20/24 4:39:36 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    $CTCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    11/14/24 2:48:40 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Carmell Corporation (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    4/18/24 3:03:07 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care